ASCO 2022 Conference Coverage

 

Lymphoma
04:26

ASCO 2022 Conference Coverage

2022 ASCO Annual Meeting "The Effects of AVM0703 Mobilization of Endogenous γδ Invariant TCR+ Bi-specific NKT-like Cells Against Solid Tumors & Blood Cancers"

FEATURING Jena Dalpez
  • 118 views
  • July 1, 2022
  • 1
01:07

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase 2 KEYNOTE-C11 Study: Sequential Pembro & Chemo in Newly Diagnosed, Early Unfavorable, or Advanced cHL

FEATURING Jane Winter
  • 42 views
  • June 24, 2022
09:39

ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 2 KEYNOTE-C11 Study: Sequential Pembro & Chemo in Newly Diagnosed, Early Unfavorable, or Advanced cHL

FEATURING Jane Winter
  • 13 views
  • June 24, 2022
01:13

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase III frontMIND Study: Tafasitamab + Lenalidomide + R-CHOP vs. R-CHOP Alone for Newly Diagnosed High-Intermediate & High-Risk DLBCL

FEATURING Umberto Vitolo
  • 42 views
  • June 24, 2022
08:45

ASCO 2022 Conference Coverage

ASCO 2022 on the Phase III frontMIND Study: Tafasitamab + Lenalidomide + R-CHOP vs. R-CHOP Alone for Newly Diagnosed High-Intermediate & High-Risk DLBCL

FEATURING Umberto Vitolo
  • 23 views
  • June 24, 2022
08:55

ASCO 2022 Conference Coverage

ASCO 2022 on the Analysis of Peripheral Neuropathy in 1L DLBCL Using ClinROs and PROs in the POLARIX Study

FEATURING Marek Trneny
  • 23 views
  • June 23, 2022
10:16

ASCO 2022 Conference Coverage

ASCO 2022 ADCs and CARs: Racing to Cure Aggresive Lymphoma

FEATURING Krish Patel
  • 85 views
  • June 23, 2022
  • 1
13:02

ASCO 2022 Conference Coverage

ASCO 2022 on the Predictive Value of TGFβ1/TGFBR2 Ratio for Evaluating the Effectiveness of Treatment in DLBCL

FEATURING Valeria Bandovkina
  • 106 views
  • June 21, 2022
  • 1
11:30

ASCO 2022 Conference Coverage

ASCO 2022 Expert Discussion: Current Treatment Approaches in Hemophilia

FEATURING James Bussel, Catherine Mcguinn
  • 55 views
  • June 20, 2022
01:44

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Treatment Patterns and Real-World Effectiveness of Rituximab Maintenance in Older Pts With Mantle Cell Lymphoma: A Population-Based Analysis

FEATURING Mengyang Di
  • 8 views
  • June 16, 2022
05:39

ASCO 2022 Conference Coverage

ASCO 2022 Treatment Patterns and Real-World Effectiveness of Rituximab Maintenance in Older Pts With Mantle Cell Lymphoma: A Population-Based Analysis

FEATURING Mengyang Di
  • 99 views
  • June 16, 2022
05:16

ASCO 2022 Conference Coverage

ASCO 2022 Three-Year Follow-Up of Outcomes With KTE-X19 in R/R Mantle Cell Lymphoma in ZUMA-2 Trial

FEATURING Michael Wang
  • 92 views
  • June 15, 2022
53

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Three-Year Follow-Up of Outcomes With KTE-X19 in R/R Mantle Cell Lymphoma in ZUMA-2 Trial

FEATURING Michael Wang
  • 33 views
  • June 15, 2022
05:40

ASCO 2022 Conference Coverage

ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma: Real-World Experience From the United States Lymphoma CAR-T Consortium

FEATURING Preetesh Jain
  • 87 views
  • June 15, 2022
57

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma: Real-World Experience From the United States Lymphoma CAR-T Consortium

FEATURING Preetesh Jain
  • 13 views
  • June 15, 2022
07:46

ASCO 2022 Conference Coverage

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLARGO Trial: Polatuzumab Vedotin + Rituximab, Gemcitabine, and Oxaliplatin in R/R DLBCL

FEATURING Matthew Matasar
  • 76 views
  • June 14, 2022
03:32

ASCO 2022 Conference Coverage

ASCO 2022 Correlates of Common Concerns in Older Cancer Survivors of Leukemia and Lymphoma: Results From the WHI-LILAC Study

FEATURING Melissa Loh
  • 19 views
  • June 10, 2022
52

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Real World Experience of Combined Treatment With Romidepsin & Azacitidine in Peripheral T-Cell Lymphoma

FEATURING Matko Kalac
  • 18 views
  • June 9, 2022
12:56

ASCO 2022 Conference Coverage

ASCO 2022 Real World Experience of Combined Treatment With Romidepsin & Azacitidine in Peripheral T-Cell Lymphoma

FEATURING Matko Kalac
  • 16 views
  • June 9, 2022
01:33

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy for WM: An International Collaborative Study

FEATURING Jithma Abeykoon
  • 102 views
  • June 9, 2022
10:06

ASCO 2022 Conference Coverage

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy for WM: An International Collaborative Study

FEATURING Jithma Abeykoon
  • 1,665 views
  • June 9, 2022
  • 6
42

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Clinical & PROs in a Phase III, Randomized, Open-Label Study Evaluating Axicabtagene Ciloleucel vs. SoC Therapy in Elderly Pts With R/R LBCL

FEATURING Jason Westin
  • 24 views
  • June 9, 2022
05:27

ASCO 2022 Conference Coverage

ASCO 2022 on Clinical & PROs in a Phase III, Randomized, Open-Label Study Evaluating Axicabtagene Ciloleucel vs. SoC Therapy in Elderly Pts With R/R LBCL

FEATURING Jason Westin
  • 58 views
  • June 9, 2022
04:35

ASCO 2022 Conference Coverage

ASCO 2022 on CRC-403: A Phase 1/2 Study of bbT369, A Dual Targeting CAR T-Cell Drug Product With a Gene Edit, in R/R B-Cell NHL

FEATURING Frederick L. Locke
  • 52 views
  • June 9, 2022
34

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Study of Tazemetostat in Combination With Lenalidomide & Rituximab in R/R FL

FEATURING Connie Lee Batlevi
  • 19 views
  • June 8, 2022
05:16

ASCO 2022 Conference Coverage

ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Study of Tazemetostat in Combination With Lenalidomide & Rituximab in R/R FL

FEATURING Connie Lee Batlevi
  • 64 views
  • June 8, 2022
05:13

ASCO 2022 Conference Coverage

ASCO 2022 PACIFIC Trial Updates: Response Kinetics, Safety & Efficacy of Brentuximab Vedotin & Nivolumab +/- R-CHP for Untreated PMBL

FEATURING Raphael Steiner
  • 413 views
  • June 7, 2022